Acamprosate improve control of drinking as well as aiding abstinence? International Conference: Setting the standard in treatment of alcohol-dependence

Chick, J. Lehert, Philippe [FUCAM]

(eng) Data on patients' alcohol consumption from 15 placebo-controlled treatment studies (n=3309) were examined to test whether, at a given time point, patients who have taken one or more drinks since the last assessment (‘relapsers', n=1010) take alcohol on fewer days, report lower average number of drinks per day, and consume less alcohol in total, with acamprosate than with placebo. These studies had varying duration, 90 days, 180 days and 360 days. There were 4 dates which at least some studies had in common: Day 30, 90, 180 and 360. Results: Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of drinking than placebo, in each of the four follow-up periods (p<0.001). The differences were most marked for the product Q*F, the overall weekly consumption. For each period there were fewer who were drinking an average of 5 or more drinks per day in the acamprosate than in the placebo groups. Conclusion: Acamprosate helps reduce the severity of a r

(fre) Les données de consommation des patients relatifs à 15 essais contrôlés-randomisés (n=3309) ont été agrégées au sein d'une meta-analyse , en vue d'étudier la probabilité de récidive d'un patient, en fonction de l'existence de multiple récédives antérieures. Les données disponibles existaient à J30? J180 et J360. Resultats: Parmi les recidivistes, acamprosate a significativement diminué la fréquence de consommation, la consommation moyenne journalière, et en consequence, le total produit (p<.001). c'est d'ailleurs sur cette dernier variable que les differences sont les plus marquees. Enfin, on a mis en evidence que la proportion des patients non contrôlés (consommant plus de 5 drinks/jour) été significativement moins élevée dans le groupe placebo. Conclusion: acamprosate est caractérisée par un effet bénéfique de reduction de consommation, et reduit la la sévérité de la récidive sur des patients traités